A REVIEW ON IN VIVO AND IN VITRO EXPERIMENTAL MODELS TO INVESTIGATE THE ANTI-INFLAMMATORY ACTIVITY OF HERBAL EXTRACTS

INAYAT KABIR, IMTIYAZ ANSARI*
Department of Pharmacology, Oriental College of Pharmacy, Sanpada, Navi Mumbai - 400 705, Maharashtra, India.
Email: imtiyaz.ansari@ocp.edu.in

Received: 24 April 2018, Revised and Accepted: 04 July 2018

ABSTRACT

The article emphasizes the anti-inflammatory effects of herbal extracts on different experimental models that are repeatedly used to test the in vivo anti-inflammatory activity of herbal components. Edema, granuloma and arthritis models are used to test the anti-inflammatory activity of plant extracts whereas formalin or acetic acid-induced writhing test and hot plate methods are the most repeatedly used to evaluate anti-nociceptive potentials of the herbal extracts. Although adjuvant-induced and collagen-induced arthritis models are also quite efficient, they have been used seldom to evaluate anti-inflammatory tendencies of the herbs. Here, we suggest a double positive reference model using both steroid and nonsteroidal anti-inflammatory drugs at the same time, instead of using only one of them either.

Keywords: Anti-inflammatory, Herbal extracts, Experimental models, Carrageenan.

INTRODUCTION

Inflammation is the response of the living system to cell injury. It is a protective mechanism that helps the body to identify and neutralize the noxious stimuli such as bacterial pathogens, toxic chemicals, and cancerous cells by increasing the blood flow to the area of tissue injury. Inflammation is also a great hazard to the patient. It increases the ulceration and sufferings of the patient due to pain and morbidity. Arachidonic acid, cyclooxygenase, and lipoxygenase-mediated activation of local inflammatory mediators such as leukotrienes, prostaglandins, prostacyclin, thromboxane A2, and platelet-activating factor play a key role in tissue destruction and pain associated with inflammation [1,2]. Inflammation often results in pus formation that may hinder the absorption of different antibiotics into the affected tissue that leads to the aggravation of tissue destruction. Hence, it becomes mandatory to administer anti-inflammatory drugs to cure a number of disorders such as infectious diseases in combination with antibiotics. Although a number of different synthetic and semi-synthetic drugs are in use today to combat inflammation, there has always been a thirst to search for the natural anti-inflammatory constituents from various plants and spices. The medicinal importance of spices [63] and herbs is known since ancient times. Most of the today’s allopathic medicines are either consisted of herbal extract, or these are the semi-synthetic derivatives of herbal products. Since prehistoric times, herbs are famous in traditional medicine for their anti-inflammatory, antinociceptive, and immunomodulatory activities. Many researchers have directly tested the inhibitory effect of different herbal extracts on the production of inflammatory mediators using different cell culture techniques [3-5]. Such in vitro studies are helpful in developing an understanding of the mechanism of anti-inflammatory activity of herbal compounds; however, most of such in vitro studies are secondary to a preliminary in vivo evaluation of anti-inflammatory properties of plant extracts [6-9]. Different researchers have used different experimental models to evaluate the anti-inflammatory activity of herbal extracts. Here, we have summarized all those in vivo and in vitro methods that are repeatedly being used to evaluate the anti-inflammatory activity of herbs and spices.

IN VIVO SCREENING MODELS

In these in vivo screening methods, the potency of anti-inflammatory agents is measured by inducing the inflammation in experimental animals such as rats, mice, monkeys, and dogs of either sex can be used. The inflammation inducers used commonly are carrageenan, mustard, dextran, egg-white, compound 48/80, Yeast, Zymosan-LOX, Serotonin, histamine, Kaolin, Substance –p, nystatin, glass powder, cobra venom, etc. Before starting any in vivo assay, it is important to study the oral acute toxicity study for the selection of test dose. In this, maximum tolerated and minimum toxic dose are calculated by injecting the test dose at an interval of 2 h in 10, 50, 100, 200,…, 2000 mg/kg patterns [10].

Experimental animals

Some researchers have used big ear albino rabbits [10] most of them have preferred using mice and rats to test the anti-inflammatory activities of herbal extracts. Different types of mice and rats that are frequently used to test the anti-inflammatory effect of herbs include ICR mice [6-8,11-13], Sprague Dawley (SD) rats [6,11,13-16], ddY mice [2], BALB/c [18] and its sub-strain BALB/cj mice [12], C57BL/6 commonly called as black 6 [4], Swiss albino mice [19,20], albino rats [21], and Wistar rats [20,22]. The animals are allowed free access to food (Laboratory chow) and tap water ad libitum. They are accommodated in a specific pathogen-free animal facility (in a laminar air flow room), at a suitable temperature of 22±1°C and 40–60% RH in a light/dark cycle of 12 h [11,12] for 2 weeks or more.

Types of screening methods

Based on the symptoms observed during inflammation in vivo screening methods for anti-inflammatory drugs are characterized into three phases as below [42].

Acute or transient phase

Vasodilation and increased capillary permeability are perceived.

Sub-acute phase

In this, infiltration of leukocytes and phagocytes in blood is observed.

Chronic inflammatory phase

Here, granuloma that is tissue degeneration and fibrosis was observed.

IN VIVO SCREENING MODELS

Carrageenan-induced paw edema in rats [1,23,27,28,42,61,62]

A solution of carrageenan in saline is injected subcutaneously in rats induces an acute swelling that becomes maximal after 3–5 h of the
injection and subsides by 24 h [60]. The inflammation produced in this model can be used to measure the production of inflammatory mediators at sites of inflammation, the anti-inflammatory properties of nonsteroidal anti-inflammatory drugs, the efficacy of alleged analgesic compounds to reverse cutaneous sensitivity. This method produces and measures carrageenan-induced inflammation in the footpad, which can be marked as edema and hypersensitivity.

Materials list [60]
- Male or female rats weighing >100 g
- 0.5–2.0% (w/v) carrageenan solution (Type IV Lambda, Sigma)
- 0.9% (w/v) sterile saline
- Ethanol (70%, v/v)

Reagents and solutions
Carrageenan: 0.5–2.0% (w/v) carrageenan solution.

Pour 500 ml of sterile 0.9% saline into a 1 L beaker and give a stir. Slowly add 2.5 g (0.5%)–1.0 g (2.0%) carrageenan powder to the beaker. Heat the solution to 90°C with continuous stirring; do not allow the solution to boil. Heating the mixture helps to dissolve the carrageenan; it takes <1 h to dissolve all of the powder. Pour the solution into a clean and sterile 1 L glass bottle. After cooling the solution at room temperature equipped into sterile, 100 ml capped bottles. This solution is stable for at least 1 week when stored at 4°C [44].

Evaluation
Measure the paw volume using plethysmometer or micrometer at 3 and 6 h, eventually at 24 h immediately after the injection. Calculate the increase in paw volume at 3 and 6 h. The percentage increase in paw volume was measured by comparing the difference of the average values between treated group animals and control group animals is calculated at each interval of time. A dose-response curve is run for the active drugs to determine the ED50 values. The treated group animals show much less edema than control group animal [42].

Calculations:
\[
\% \text{ edema produced by carrageenan alone} = \frac{A-B}{B} \times 100 = X \%
\]
\[
\% \text{ edema produced by carrageenan after treating with drug} = \frac{C-D}{D} \times 100 = Y \%
\]
\[
\% \text{ reduction of edema by drug} = \frac{X-C}{X} = --- \% [45].
\]

Crotone oil-induced ear edema
In this method both rats and mice are used, usually male rats (SD) of 80–60 g are selected, whereas male Swiss mice weighing between 18 and 22 g are selected. They are grouped according to the body weight.

In this approach, a total of 15μl containing an acetonic solution of 75 μg of crotone oil is applied to the inner surface of the right ear of each mouse. The animals are previously, anesthetized with diethyl ether at a rate of 0.02 ml in rats and 0.01 ml in mice [1,34,44].

Evaluation
Evaluate the degree of erythema by the double-blind method. The following scores are given:
0 - No erythema
1 - Weak erythema
2 - Strong erythema
4 - Very strong erythema

Animals with a score of 0 or 1 are said to be protected. The scoring after 2 and 4 h indicates some duration of the effect and ED_{50} values can be calculated [46].

Pleurisy in rats
Methodology
The animal used in the pleurisy test is the mouse. Inject a single dose of 0.1 ml carrageenan intravenously. After 4 h kill the animal
with an overdose of ether and wash the pleural cavity with 1.0 ml of sterile phosphate-buffered saline (PBS), containing heparin (20 IU per ml). Collect the samples of the pleural lavage and determine the exudation, nitric oxide (NO) levels, adenosine deaminase activities, myeloperoxidase, and total differential leukocyte counts. Perform total leukocyte counts in a Neubauer’s Chamber. Analyze the serum level of the C-reactive protein. In another set of experiment treat animals with a solution of Evans blue dye (25 mg/kg, iv), 30 min before carriageen so as to evaluate the degree of exudation in the pleural space [43].

Estimate the amount of dye at 600 nm by colormetry using an ELISA Plate Reader, by interpolation from a standard curve of Evans Blue Dye in the range of 0.01–50 µg/ml.

**Evaluation**

Average and compare the values of each experimental group with that of control. Calculate ED$_{50}$ values using various doses.

**Granuloma air pouch techniques**

**Methodology**

The animals used in this method were male or female SD rats with a body weight between 150 and 200 g. Take 10 animals for control and test groups. Shave and disintact the back of the animals. Make a pneumoderma, by injecting 20 ml of air under ether anesthesia in the middle of the dorsal skin with a very thin needle, which results in an oval air pouch. Inject 0.5 ml of a 1% solution of croton oil in sesame oil, avoiding any leakage of air. Remove the air pouch after 48 h [44].

• Inject the test compound directly into the air sac at the same time as the irritant.
• Sacrifice the animals on the 4th or 5th day under anesthesia.
• Open the pouch and collect the exudate in glass cylinders.
• Evaluate total number of leukocytes migrate into the pouch are after staining with erythroine B.

**Evaluation**

Calculate the average value of the exudates of the control and the test groups. Compare it by statistical means.

**Increased vascular permeability by arthus reaction**

**Methodology**

In this method ALBINO Wistar rats are used. 4 rats in each group. Administer distilled water, 1% w/v 1 ml/100 g by oral route to control group and the test compound to another group by oral route and to the standard group diconfenac 10 ml/kg by intraperitoneal route. 1 h after the administration, inject rats with 0.25 ml of 0.6% v/v solution of acetic acid intraperitoneally [50]. Immediately inject 10 ml/kg of 10% w/v of Evans blue intravenously through the tail vein. Anesthetize the animals after 30 min, with ether anesthesia and sacrifice. Cut the abdomen, open and expose viscera. Hold the animals by a flap of abdominal wall over Petri dish. Collect the perioteal fluid (exudates), filter and make up the volume up to 10 ml using normal saline solution and centrifuged at 3000 rpm for 15 min. Measure the absorbance (A) of the supernatant at 590 nm by means of spectrophotometer [56].

**Evaluation**

The decrease in the concentration of dye with respect to absorbance indicates the reduction in permeability.

**Adjuvant arthritis [29]**

Freund’s complete adjuvant-induced arthritis in rat model is the most widely used experimental model for arthritis with clinical and laboratory features that closely mimic the clinical features of human rheumatoid disorder [1,32,33,49]. This model is sensitive to anti-inflammatory and immnosuppressive medicines and considers being appropriate for the study of pathophysiological and pharmacological control of inflammation progression as well as for the evaluation of the potential of analgesic drugs.

**Methodology**

On day zero, inject animals with 0.1 ml of complete Freund’s adjuvant (FA) into the subplantar region of the left hind paw. This consist of 6 mg of Mycobacterium butyricum suspended in heavy paraffin oil by grinding with mortar and pestle to give a concentration of 6 mg/ml. Administer dosing with the test and standard compounds on the same day and continue for 12 days as per the following schedule. From day 13$^{th}$ to 21$^{st}$, do not dose the animals with the test or the standard compound. Evaluate by comparing certain parameters between the control and treatment.

**Papaya latex-induced arthritis**

Papaya latex-induced arthus model of experimental rheumatoid arthritis has been developed to test the anti-inflammatory effect of slow reaction antirheumatic drugs. Papaya latex-induced inflammation is supposed to be mediated through prostaglandines [44,46,47].

**Methodology**

Prepare 0.25% solution of papaya latex to take 0.1 ml (prepared in 0.05 M sodium acetate buffer and pH 4.5 with 0.01% thymol) and inject into the rat back foot (hind paw). The peak effect occurs at 3 h and continues for more than 5 h. The method is sensitive for evaluating nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen, and nonsteroidal anti-inflammatory drugs [46,47].

**Candida albicans induced arthritis**

**Methodology**

Repeated injection with Streptococcus pyogenes cell wall (SCW) fragments into the knee joint of C57Bl/6 mice produces chronic SCW arthritis alone or in combination with the yeast of C. albicans or Zymosan, A. Perform the cytokine levels, mRNA expression and histopathological analysis of the joints during the chronic phase of arthritis. Investigate the phenotype of the interleukin (IL)-17 producing T-cells, isolate and analyze synovial cells by flow cytometry [45].

**Arachidonic acid-induced ear edema in mice**

**Materials**

Obtain arachidonic acid, fatty acids, eicosanoids, and histamine (Base). Dissolve the compounds in a 1:1 (v/v) mixture of tetrahydrofuran and methanol (HPLC grade, Rathbun). CD1 male mice (weighing 20–25 g) and Tuck Wistar male rats (weighing 120–140 g) are used [57,53,54].

**Methodology**

Apply 2 mg arachidonic acid in 10–1 tetrahydrofuran:methanol to the inner surface of each ear. Use various amounts of arachidonic acid in ethanol for initial dose-dependency studies. Compounds tested for their inhibitory capacity are normally incorporated in the arachidonic acid solution and applied only to the left ear. Give the only solvent to the control animals on each ear. Kill the animals after 1 h by cervical dislocation and cutoff both ears at the hairline and weigh. Assess the swelling induced by arachidonic acid as an increase in the weight of the right ears over that of the right ears of solvent-treated control animals, as an amount of the weight of solvent-treated right ears. The swelling induced in the same animals in the presence of test compound was likewise the increase in the weight of the left ears over that of the left ears of the control animals expressed as a proportion of the weight of solvent-treated left ears [52-54].

This value is expressed as percentage of the full (right ear) swelling, and hence a percentage inhibition by the test compound is calculated:

\[
\text{Inhibition} = \frac{1 - \text{(proportional swelling of test compound)} \times 100}{\text{(in absence of compound)}} \times 100
\]

where

\[
x = \text{average weight of the left control ears}
\]

\[
y = \text{average weight of the left control ears}
\]
content enzyme levels and biological mediators such as prostaglandins. For the estimation of fluid phase of sponge exudates, for example, protein evaluation and maintain the animals at a constant temperature of 24°C [51].

Implant up to 8 sponges per rat. Close the insertion with Michael clips forming separate cavities into which the sponges can be inserted. One can form a subcutaneous tunnel in the cranial direction with closed skin edges. Anesthesia. Make a 20 mm dorsal incision and separate the dermis from the underlying muscle layer by insertion of blunted forceps to the end, under CO₂ anesthesia. The glass rod is prepared with adjacent tissue which forms a tube around the glass rod. Record wet weight of the granuloma tissue, finally dry it and record the dry weight [23, 48, 49].

**Evaluation**

Calculate the weight of transudate and the granuloma as well as the percent granuloma inhibition of the test drug. Record the body weight gain also.

**Glass rod granuloma**

**Methodology**

In this technique, select a glass rod with a diameter of 6 mm and 40 mm length. Select male SD rats with an initial weight of 130 g. Anesthetize these rats with ether. Shave and disinfect their back skins. Form a subcutaneous tunnel in the cranial direction with closed blunt forceps by an incision in the caudal region. Introduce the glass rod into this tunnel which lies on the back of the animal. Close the incision wound using sutures. Keep the animals in separate cages; the rods remain in situ for 20 or 40 days. Sacrifice the animals at the end, under CO₂ anesthesia. The glass rod is prepared with adjacent connective tissue which forms a tube around the glass rod. Record wet weight of the granuloma tissue, finally dry it and record the dry weight also [44, 50, 51].

**Evaluation**

Compare granuloma weight reduced by the test compound with that of the standard.

**Sponge implantation technique**

**Methodology**

Prepare the sponges for implantation from polyvinyl foam sheets with a thickness of 5 mm discs and stamped out to a standard size and weight (10.0±0.02 mg) using a 13 mm cork tool. Soak the sponges in 75% v/v ethanol for 30 min, and then heat at 80°C for 2 h. Before implantation in the animal, soak the sponges in sterile 0.9% saline which may contain either drugs or antibiotics or irritants suspended in it. Implant the sponges in female Wistar rats weighing about 150–200 g under ether anesthesia. Make a 20 mm dorsal incision and separate the dermis from the underlying muscle layer by insertion of blunt forceps to form separate cavities into which the sponges can be inserted. One can implant up to 8 sponges per rat. Close the insertion with Michael clips and maintain the animals at a constant temperature of 24°C [51].

**Evaluation**

For the estimation of fluid phase of sponge exudates, for example, protein content enzyme levels and biological mediators such as prostaglandins as well as for leukocyte migration, remove sponges after 9 h.

---

**Dextran sulfate sodium-induced colitis in mice**

This is a new experimental model of colonic inflammation introduced by Okayasu et al. [1]. This model mimics the clinical and pathological features of human ulcerative colitis. It is induced by oral administration of sodium dextran sulfate (DSS), which disrupts the mucosal barrier and triggers an inflammatory response.

**Animals**

Use specific pathogen-free 6-8-week-old female mice. The mice used are conventional Balb/c and barrier born nu/nu Cd-1 (BR) athymic nude mice [25]. Keep the Balb/c mice in standard laboratory conditions with free access to animal chow. By keeping the nu/nu Cd-1 animals in disposable cages with filter tops. Radiate-sterilize bedding and autoclave animal chow (R34) for use and keep the animal room and facilities aseptic by spraying them with an aqueous solution of Benzalkonium chloride.

**Induction of colitis**

Induce colonic inflammation by the administration of DSS in the drinking water. Dissolve DSS with Mw 40–44 kDa and a sulfur content of 15.4–17.0% in ultra-pure water at concentrations of 2.5% and 5.0% with a final pH of 8.5. Assess the characteristics of the DSS and its stability in solution [7]. Expose the animals to different DSS solutions ad libitum. Test the water and DSS for bacterial endotoxin contamination.

**Inhibition of inflammatory granulation**

This method is used to study the repair phase characterized by fibroblast proliferation and blood vessel formation. Suppression of granulation tissue parallels with anti-inflammatory activity is measured [56].

**FA arthritis**

This is the immunologically mediated model of chronic inflammation. It is a delayed hypersensitivity response to mycobacterial Ag. Induction of arthritis is done by subplantar injection of Freund's complete adjuvant or mycobacteria suspended in oil [56].

**Guinea pig model of giant papillary conjunctivitis**

Chronic exposure of contact lenses to foreign bodies leads to GPC. Levels of IL-3, IL-4, IL5, Ig G, Ig E, and Ig M are increased in Tears [56].

**Procedure**

Insert a sterile needle directly into conjunctiva of the unsensitized animal. This prickling results in a high number of neutrophil infiltration.

**Xylene-induced ear edema in mice**

The acute inflammatory activity of drugs is evaluated using xylene-induced ear edema in mice as previously described [58, 59]. Divide the mice randomly into the following five treatment groups of eight animals each: Vehicle control (distilled water, 20 mL/kg, p.o.), ASA positive control (100 mg/kg, p.o.), and three doses of drug (0.8, 2.4, and 7.2 g/kg, p.o.). Administer these treatments orally for 6 consecutive days. On day 7 at 1 h after oral administration, apply 30 µl of xylene on both the surfaces of the right ear to induce edema. The left ear served as a control. Sacrifice the mice 30 min after xylene treatment by i.p. injection of sodium pentobarbital (60 mg/kg ad libitum).
performing cervical dislocation. Remove the right and left ears of the mice with 8 mm diameter cork borer and weigh the ears. Measure the edema weight difference between the right and left ears of the same animal. Compare the percentage of inhibition with the control group and calculate using the following formula: %Inhibition = [(Weight of edema (control) − Weight of edema (test)])/Weight of edema (control) × 100 [40].

Monosodium urate crystal-induced arthritis

The unmetabolized product of purine gets deposited as uric acid in the synovial joint which induces activation of kin in leukotriene B4, accumulation of neutrophil granulocytes characterized by an intermittent attack of Acute Arthritis or Gout. On this, the drugs are injected intradermally at the knee joint to produce arthritis. By injecting 20 mg sodium urate crystal suspensions in their own knee joint. They experienced severe pain and pustulation which resembled an acute gouty attack [49].

Procedure

Induce inflammation by intradermal injection of 0.2 ml (4 mg) of endotoxin-free monosodium urate crystal suspension into the right foot pad. Day considered as day 0–3. Start treatment with standard and test from day 0 before half hour of MSU and continue for 3 days.

Preparation of monosodium urate crystals

Dissolve about 4 g of uric acid in 800 ml water and heat with NaOH (9 ml/0.5 N), adjust pH to 8.9 at 60°C; cool overnight in a cold room; wash and dry. Recover needle-like crystals and suspend in sterile saline (20 mg/ml).

Grip strength of arthritic animals

In this method, the inducer of arthritis is silver nitrate which is injected in the tibiotarsal joint of rats or by means of intra-articular t alc injections in pigeons. This impairs the locomotor activity with inflamed paws. Effective drugs are NSAIDs, steroids, DMARDs, and anti-histamines [56].

Inhibition of NO production induced by tumor necrosis factor-alpha (TNF-α) in mouse macrophages

Animals

Mice C57BL/6.

Infection and treatment with mAb against TNF-α

Subcutaneously infect resistant C57BL/6 mice in the footpad with 2×10^6 promastigote forms in stationary phase. Inject the animals i.p. with 500 μg anti-TNF-α mAb (XT22.11), 2 h before the infection, followed by twice a week until the 12th week after infection. Control mice are untreated or treated with 500 μg rat purified immunoglobulin G (IgG). For 3 days before the infection, treat the animals with nigel or anti-TNF-α were daily treated orally with 5 mg rat IgG, to make them tolerant to IgG [21,41].

Determination of disease progression

Monitor the development of lesions by measuring the increase in footpad thickness as compared to the uninjected one. Determine the number of parasites in the lesion by a modified limiting dilution analysis applying Poisson statistics and the χ²-minimization method, using a computer program (ELIDA) [55].

Determination of serum nitrate concentration

The nitrate (NO₃⁻) present in the serum samples are obtained from infected and TNF-α mAb-treated animals and are reduced to nitrite with nitrate reductase and determine the nitrate concentration by the Griess method [26,56].

Inducible nitric oxide synthase (iNOS) activity assay [39]

Collect the popliteal lymph nodes from C57BL/6 mice treated with anti-TNF-α, nigel or saline at the 2nd, 6th, and 12th weeks after infection with L_major, and determine iNOS activity by measuring the formation of ¹⁴C citrulline as described [57]. iNOS activity is expressed as pmol citrulline/mg protein/h.

Immunolocalization of iNOS in macrophages and neutrophils on footpad lesions

Insert the footpad tissues and draining lymph nodes in OCT compound, freeze and store at ~70°C. Place the tissue sections of 5 μm thick, on L-poly-lysine-coated slides fixed in acetone, and block nonspecific protein binding with goat serum (diluted 1:200 in PBS) for 45 min. Incube the slides with primar rabbit anti-mouse iNOS antibody (Santa Cruz Biotechnology, CA; diluted 1:200 in PBS plus 1% BSA) overnight. The reaction product is detected with avidin-biotin-peroxidase complex (Vector Laboratories, Burlingame, CA), and develop the color of the reaction with diaminobenzidine tetrahydrochloride (DAB; Sigma, St. Louis, MO). Counterstain the slides with Mayer’s hematoxylin. Score the observed intensity of the reaction on the slides as absent, discrete, moderate, or intense [55,56].

IN VITRO SCREENING MODELS

COX assay

COX-1

Add 10 ml of the sample solution to 19 ml of 0.1M of L-adrenaline, dihydroxytartrate, and 10 mM of hematin. After adding 0–2 units of COX-1 pre-incubate for 5 min by adding 10 ml of 10% formic acid. Measure the PGE2 concentration with a PGE2 enzyme immune assay [41].

COX-2

Prepare assay mixture with 100 mm rod phosphate, 1 mm of hematin gelation, 2.5 ml of the compound in DMSO. It is to be pre-incubated for 15 min at 22°C and add the 20 ml of 1 mArachidonic acid solution and 1 mM Thermal power management device (TPMD) in assay buffer. Measure the absorbance at 400 nm over the fast 36 s and calculate percentage inhibition. Observe the enzyme inhibition of TPMD in the absence of COX-2 and subtract from activity in the presence of COX-2 [35,41].

Mast cell degranulation

Inject heparinized Tyrode solution into the peritoneal cavity of exanguinated rat (SD) after the abdominal massage, harvest and separate the cells in peritoneal fluid through 38% Bovine Serum Albumin. Wash the cells and suspend in Tyrode solution with 0.1% BSA. Pre-incubate the cell suspension with test drugs at 37°C for 3 min, 15 mins after addition of compound 48/80 (standard compound for mast cell degranulation), glucuronidase (1 mM Phenolphthalein-β-d-glucuronide in 0.1 M acetic acid buffer; pH 4.5 is used as a substrate, and monitor absorbance at 550 nm after alkalization), and histamine (0.2% o-phthalaldehyde condensation in pH 12.5 fluorescence is monitored at 350/450 nm after acidification) in the supernatant is determined. Measure the total content after treatment of the cell suspension with Triton X-100. Determine the percent release as the index of anti-inflammatory activity [41].

Platelet-neutrophils adhesion

Thrombin-activated human platelets are incubated with the drug at 20°C for 10 min and mixed with neutrophils at a ratio of 10:1. Neutrophil-Thrombin-activated human platelets are incubated with the drug at 20°C for 10 min and mixed with neutrophils at a ratio of 10:1. Neutrophil-neutrophils adhesion

Platelet-neutrophils adhesion

Cells viability

Cell viability is evaluated using a 3-(4,5-dimethyl-thiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)-based colorimetric assay (Diaz-Lanza et al., 2001). Pipette cells (8×10⁶) diluted with Dulbecco’s modified Eagle’s medium with 10% heat-inactivated fetal calf serum (FCS) into 96-well microtiter plates and were incubated overnight at 37°C and 5% CO₂. They were exposed to various concentrations of samples for 3h under the same conditions of incubation. MTT solution dissolved in phosphate-buffered saline was added to the wells at
1mg/ml final concentration. After carefully aspirating the medium, 100 μL of DMSO was added for the dissolution of formazan crystals. The absorbances of all wells were then read at 520 nm using a microplate reader. The values of the maximum non-toxic concentration obtained were used in PGE, and LTB4 determination [41].

Apart from these methods following methods are used for the screening of anti-inflammatory drugs:

- Formalin induced paw oedema [24, 36]
- Streptococcal cell wall (SCW) arthritis [30]
- Collagen-induced arthritis (CLIA) mouse model [31]
- Cell-based reporter gene assay
- FML-Induced adhesion of PMN of HUVEC
- 3-H bradykinin receptor binding [49]
- 3-H Substance P receptor binding
- Assay of PMNL chemotaxis
- PMNL aggregation constitutive and inducible cellular arachidonic acid metabolism
- Formation of leukotriene B4 in human white blood cells
- Formation of lipoygenase products from 14C-arachidonic acid in human PMN
- Formation of eicosanoids from 14C-arachidonic acid in human platelets
- Bovine serum-induced inflammation [37]
- HRBC membrane stabilization method.

ACKNOWLEDGMENT

We are grateful to our Principal Dr. (Mrs.) Sudha Rathod, Dr. (Mrs.) Vanita G. Kanase, and Dr. Sayed Mateen for their guidance and support as well as to Pharmacology Department, Oriental College of Pharmacy, Navi Mumbai.

AUTHOR’S CONTRIBUTIONS

We declare that this work was done by the authors named in this article and all liabilities pertaining to claims relating to the content of this article will be borne by the authors. Ms. Inayat I. Kabir collected the data and analyzed the data. Mr. Imtiaz Ansari proof-read the whole manuscript, and suggested the necessary changes, and helps in designing manuscript.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest regarding the publication of this paper.

REFERENCES


57. Fehrenbacher JC, Vasco MR, Duarte DB. Models of inflammation: Carrageean- or complete Freund’s adjuvant (CFA)-induced Edema and hypersensitivity in the rat. Curr Protoc Pharmacol 2012;Chapter 5:Unit5.4.


63. Fehrenbacher JC, Vasco MR, Duarte DB. Models of inflammation: Carrageenan- or complete Freund’s adjuvant (CFA)-induced Edema and hypersensitivity in the rat. Curr Protoc Pharmacol 2012;Chapter 5:Unit5.4.